Product logins

Find logins to all Clarivate products below.


Obesity / Overweight – Landscape & Forecast – Disease Landscape & Forecast (G7)

Obesity is a significant and growing public health concern in the G7 countries. The body of evidence highlighting the medical and economic impact of obesity on society is steadily increasing. Despite the disease’s prevalence, approved drugs are scarce compared with other chronic metabolic diseases, especially in Europe and Japan. However, the development pipeline is strengthening with novel agents that promise to address some of the limitations of current treatments. There is a huge market opportunity for antiobesity drugs that elicit greater and sustained weight loss and are safe, well tolerated, and affordable. However, given the prevalence of obesity, even if such agents are developed and approved, payers will likely need to restrict their access to limit the strain on finite healthcare budgets.

Questions answered

  • Which metabolic and central pathways have high potential as drug targets?
  • What is the prevalence of obesity in the major pharmaceutical markets under study?
  • How is obesity currently treated? What do experts think about Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide) as treatments for obese / overweight patients?
  • What is the commercial potential of emerging therapies? How do leaders in the field of obesity management rate these drug candidates?
  • How will the obesity therapy market evolve over the next 10 years?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Key features

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations

Table of contents


Related Market Assessment Reports

Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a condition heavily treated with an array of drug classes. Although the MDD drug market is dominated by generic therapies, the heterogeneous response of MDD…
Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 722 currently available and novel biosimilar products, detailing…
Report
Epilepsy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…